By Ann Czarnik, M.D., FACEP — Board-Certified Emergency Medicine Physician and Co-Founder, Amanecia Health
If you’re researching GLP-1 weight loss medications, you’ve probably run into a confusing divide. On one side, there are brand-name medications like Wegovy, Ozempic, Mounjaro, and Zepbound — manufactured by Novo Nordisk and Eli Lilly, FDA-approved, and widely advertised. On the other side, there are compounded versions of semaglutide and tirzepatide — prepared by compounding pharmacies, often at a lower cost, and prescribed by a growing number of telehealth startups and clinics.
Most of what you’ll read online pushes you toward one or the other. Telehealth companies that only offer compounded medications will tell you brand-name is overpriced. Pharmaceutical companies will tell you compounded versions are unregulated. Neither side is giving you the full picture.
I completed my Emergency Medicine residency at Johns Hopkins, where I served as Chief Resident, and I’ve spent nearly 17 years practicing in Austin — including almost a decade running the EM residency program at Dell Medical School. At Amanecia Health, we prescribe both brand-name and compounded GLP-1 medications, and the right choice depends on the individual patient, not on which one has a better margin or a bigger marketing budget.
Here’s what I think you should actually understand before making a decision.
What Brand-Name Actually Means
Brand-name GLP-1 medications — Wegovy and Ozempic (semaglutide) from Novo Nordisk, and Mounjaro and Zepbound (tirzepatide) from Eli Lilly — have gone through the full FDA approval process. That means large-scale clinical trials, rigorous manufacturing standards, and ongoing FDA oversight of every batch produced.
When you receive a brand-name medication, you’re getting a product with a known concentration, known purity, and a well-documented side effect profile. The dosing is standardized. And the clinical data behind it — including cardiovascular outcomes, weight loss percentages, and long-term safety — comes from trials involving tens of thousands of patients.
For patients who want the most thoroughly studied version of these medications with the most regulatory oversight, brand-name is the straightforward choice.
For patients who prefer a brand-name tirzepatide option, Amanecia can prescribe and help coordinate fulfillment through authorized channels such as LillyDirect, when appropriate.
What Compounded Actually Means
Compounded semaglutide and tirzepatide are not the same medications as their brand-name counterparts. They are pharmacy-prepared formulations using the active pharmaceutical ingredient, but they are not FDA-approved, have not been evaluated for bioequivalence, and may differ in formulation, concentration, and composition.
That said, compounding has a long and legitimate role in medicine — and for many patients, compounded GLP-1 medications are the better practical option. Compounding pharmacies that meet USP 795 and 797 standards operate under state board of pharmacy oversight and follow specific preparation and testing protocols. They offer physicians flexibility in dosing and formulation that brand-name products don’t always provide.
One distinction patients often notice is that most compounded GLP-1 formulations include vitamin B12. Compounding pharmacies add B vitamins because they can support energy levels and overall metabolic health during weight loss treatment — an advantage that brand-name formulations don’t offer.
Not all compounding pharmacies are equal. Quality varies, and the safety and accuracy of a compounded medication depends on the pharmacy preparing it. This is one of the most important reasons your prescribing physician matters. A doctor who understands the compounding landscape can source from pharmacies they’ve vetted, rather than leaving you to guess which online vendor is trustworthy.
The Real Differences You Should Know About
Beyond the regulatory and sourcing distinctions, there are practical differences that affect your experience as a patient.
Cost. Brand-name GLP-1 medications carry a higher price point, particularly without insurance coverage. Compounded versions are typically less expensive. For many patients, this is the deciding factor — and it’s a legitimate one. But cost should be weighed alongside the other factors below, not treated as the only variable.
Delivery format. Both compounded and brand-name GLP-1 medications are available in multi-dose vials. Lilly has also offered pre-filled pens for its brand-name products, though vials are the standard in compounding and the format we use at Amanecia. Vials allow physicians greater flexibility when adjusting doses during treatment, which is particularly valuable during titration when patients may benefit from smaller or more individualized increments.
Dose flexibility. Compounded formulations can offer more granular dose adjustments. If you’re between the fixed dose steps of a brand-name product and need a smaller increment, compounding allows for that customization. This can be valuable during the titration phase when managing side effects.
Timeline and availability. Brand-name medications, particularly through programs like LillyDirect, may involve longer lead times for delivery. Compounded medications from an established pharmacy relationship can sometimes be available faster. Availability can shift based on drug shortages and demand.
Clinical evidence. The large-scale clinical trials (STEP for semaglutide, SURMOUNT for tirzepatide) were conducted with the FDA-approved brand-name formulations. The published weight loss, cardiovascular outcome, and long-term safety data comes from those specific products. That data should not automatically be assumed to apply to compounded formulations prepared outside those approval pathways. This doesn’t mean compounded versions have no clinical utility — it means the published evidence base was built on the branded products specifically, and patients should understand that distinction.
Why the Prescriber Matters More Than the Medication
Here’s the part that most online comparisons leave out: the decision between brand-name and compounded is not the most important decision you’ll make. The most important decision is who is managing your care.
A physician who only offers compounded medications can’t give you an unbiased recommendation. Neither can one who only prescribes brand-name. You want a doctor who has access to both options and makes the recommendation based on your specific health profile — your labs, your medical history, your response to the medication, and your goals.
Beyond the initial prescription, what happens next matters even more. GLP-1 medications require careful dose titration, side effect monitoring, and adjustments based on how your body responds. The difference between a good outcome and a frustrating one often comes down to whether your physician is actually paying attention — checking in regularly, adjusting your dose based on real-world response rather than a preset schedule, and being available when something comes up between appointments.
If your current provider prescribed a medication after a five-minute online form and you haven’t spoken to them since, that’s not medical oversight. That’s a transaction.
This is also where the choice between semaglutide and tirzepatide often shifts. Many patients come in asking about semaglutide because it’s the name they’ve encountered most — Ozempic has been in the news for years. But after a thorough consultation that includes lab work, health history, and a real conversation about goals, a significant number of patients end up on tirzepatide instead. Its dual-mechanism approach — activating both the GLP-1 and GIP receptors — can offer advantages in insulin sensitivity, fat metabolism, and sustained satiety that make it the better clinical fit for many patients. Some start on semaglutide and transition to tirzepatide as their treatment progresses and their physician adjusts the plan based on real-world results.
This kind of evolution in a treatment plan is exactly what proper medical oversight makes possible. Your medication should adapt to your progress, your body’s response, and your changing goals — not be locked in by whatever a telehealth app happens to stock.
How We Approach It at Amanecia Health
At Amanecia Health, we prescribe both brand-name and compounded GLP-1 medications. The recommendation depends on the patient, not the margin.
During your initial consultation, we review your metabolic panel, medical history, current medications, and goals. If brand-name is the right fit — whether for clinical reasons, insurance coverage, or personal preference — we can help coordinate fulfillment through authorized channels such as LillyDirect, when appropriate. If compounded is the better option based on your physician’s assessment, we source from licensed compounding pharmacies that follow applicable state and USP standards and that we’ve vetted directly.
More importantly, we stay involved. Our physicians do regular follow-ups, adjust dosing based on your actual response, manage side effects proactively, and remain directly accessible when questions come up. That’s the concierge model — not just access to medication, but access to a physician who knows your case.
Many of our patients started with weight loss and discovered they also wanted help with hormone health, energy, sleep, or longevity. Having one physician who understands your full picture, rather than separate providers for each concern, is how we practice.
The Bottom Line
Brand-name and compounded GLP-1 medications are both viable paths to meaningful weight loss when prescribed and managed properly. Brand-name offers the most clinical evidence and regulatory oversight. Compounded offers cost advantages, dose flexibility, and additions like B12 that support the treatment experience. For many of our patients, compounded is the better practical option — but the right choice depends on your body, your health history, your budget, and your goals.
The goal of any medical weight loss program should be safe, effective results aligned with your individual health profile and the plan you build with your physician. Some patients see rapid progress. Others need a more gradual approach. The timeline depends on your starting point, how your body responds, and what you and your doctor determine is the right pace — not on a generic protocol designed to move you through a prescription funnel as quickly as possible.
What matters more than which medication or formulation you choose is whether you have a physician who evaluated you properly before prescribing, who has access to both brand-name and compounded options, and who will stay involved in your care as your treatment evolves. If you’re getting a prescription without a conversation, without lab work, and without follow-up — reconsider who’s managing your health, regardless of which medication they’re prescribing.
If you’d like to discuss your options with a board-certified physician, we welcome the conversation.
Ann Czarnik, M.D., FACEP is a board-certified Emergency Medicine physician and Fellow of the American College of Emergency Physicians. She earned her medical degree from the Medical College of Virginia, where she was elected to Alpha Omega Alpha, the nation’s most selective medical honor society. She completed her Emergency Medicine residency at Johns Hopkins University, where she served as Chief Resident.
Dr. Czarnik spent nearly 17 years practicing emergency medicine in Austin, Texas, including nearly a decade as Assistant Program Director for the Emergency Medicine residency at Dell Medical School at The University of Texas at Austin. She held faculty appointments at both UT Austin and UT Southwestern, completed the ACEP Teaching Fellowship, and has presented nationally on emergency medicine education and clinical practice.
She co-founded Amanecia Health to deliver physician-led concierge medicine that puts the patient relationship first. She sees patients in Austin via telemedicine and in-home visits.
Schedule a consultation with Dr. Czarnik.
Compounded medications are not FDA-approved drugs. They are prepared by licensed compounding pharmacies under physician prescription and have not been evaluated through clinical trials for safety, efficacy, or therapeutic equivalence to any FDA-approved medications. This content is for informational purposes and does not constitute medical advice.